Melanoma-associated antigens contained within TRIMEL lysate (TRIMEL)

TRIMEL is a standardized lysate derived from three human melanoma cell lines (Mel1, Mel2, and Mel3) that have been heat-shocked to increase the expression of damage-associated molecular patterns (DAMPs) and heat shock proteins (Salazar-Onfray et al., 2011, Journal of Clinical Oncology). This lysate serves as a rich source of multiple melanoma-associated antigens (MAAs), such as MAGE-A1, MAGE-A3, tyrosinase, and gp100, which are essential for priming the immune system (Lopez et al., 2009, Journal of Clinical Oncology). In clinical applications, TRIMEL is typically used to pulse autologous dendritic cells, creating a vaccine known as TAPCells (Tumor Antigen Presenting Cells) (Durán-Aniotz et al., 2013, Cancer Immunology, Immunotherapy). These loaded dendritic cells then present the processed antigens to T cells, inducing a robust, polyvalent anti-tumor immune response (Aguirre et al., 2020, Frontiers in Immunology). This approach aims to overcome tumor heterogeneity and immune evasion by targeting a broad spectrum of antigens simultaneously, showing promise in improving overall survival in stage III and IV melanoma patients (Tittarelli et al., 2015, Cancer Research).

Other names

TRIMELMelanoma cell lysate TRIMELHeat-shocked melanoma cell lysateTRIMEL antigen mixture

TRIMEL acts as a polyvalent antigen source that provides a wide array of melanoma-associated antigens and danger signals to dendritic cells. Upon loading, these dendritic cells (TAPCells) migrate to lymph nodes and present the antigens via MHC class I and II molecules to CD8+ and CD4+ T cells, respectively, initiating a systemic anti-tumor immune response (Salazar-Onfray et al., 2011, Journal of Clinical Oncology).